Mr. Hugh Rogers reports

BIONXT SECURES INNOVATIVE CHAPERONE TECHNOLOGY TO ENHANCE ORAL THIN-FILM DRUG DELIVERY

Bionxt Solutions Inc. has signed a non-binding letter of intent outlining a proposed transaction pursuant to which Bionxt would secure exclusive rights to advanced drug chaperone technology for oral-dissolvable applications from a third party biotechnology developer focused on chaperone-enabled delivery systems.

The proposed transaction is intended to significantly enhance Bionxt's proprietary oral-dissolvable thin-film (ODF) platform through the acquisition and integration of variable-affinity drug chaperone technology. Bionxt believes that securing these rights has the potential to enhance drug stability, absorption efficiency and overall formulation performance in sublingual and buccal delivery -- key value drivers for reformulating approved drugs, expanding life-cycle management opportunities and strengthening platform differentiation, particularly in neurological and other chronic disease indications. The newly secured drug delivery technology is expected to target and enhance the performance of Bionxt's oral thin-film platform by improving stability, absorption efficiency and delivery consistency.

"This initiative is strategically important for Bionxt," said Hugh Rogers, chief executive officer of Bionxt Solutions. "By securing rights to chaperone-enabled delivery technology, we are strengthening our oral thin-film platform and expanding the range of drug candidates that can be effectively reformulated into fast-dissolving, swallow-free formats, including therapies for neurological diseases where consistent absorption and patient adherence are critical. This supports a scalable, IP-driven [intellectual property] growth strategy and enhances our long-term commercial potential."

Chaperone-enabled targeted delivery: enhancing drug performance

Chaperone-enabled delivery is being developed as a novel formulation and delivery approach designed to improve the performance of drug formulations through more controlled and consistent delivery at the site of administration. The technology is intended to support greater stability, absorption efficiency and predictability of drug exposure, while preserving the integrity of the underlying active pharmaceutical ingredient.

This approach has potential applicability across a broad range of therapeutic areas where reliable dosing, tolerability and patient adherence are critical. These include neurological and neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, dementia and major depressive disorder; autoimmune diseases, including rheumatoid arthritis, lupus, and diabetes; infectious diseases, including bacterial and fungal infections such as tuberculosis; as well as oncology applications, particularly solid tumours where improved delivery consistency may be relevant.

Importantly, chaperone-enabled delivery does not involve chemical modification of the drug itself. Instead, it is intended to enhance formulation and delivery performance while enabling the creation of new intellectual property around drug delivery, formulation design and targeted application.

Advancing oral thin-film technology

Oral thin films offer significant advantages over traditional solid oral dosage forms, including rapid disintegration, improved patient adherence and the potential to bypass first-pass metabolism. These attributes are especially relevant in neurological diseases, where swallowing difficulties, dosing fatigue and variable absorption can significantly impact treatment outcomes. However, the fast-dissolving environment of the oral cavity also presents technical challenges, such as limited dosing capacity, short absorption windows, and sensitivity to drug stability and solubility.

By integrating the secured chaperone technology into its ODF formulations, Bionxt aims to improve drug stability and targeted delivery performance during storage and rapid dissolution, enhance absorption efficiency without increasing dose, and expand the range of active pharmaceutical ingredients that can be reformulated into thin films. Bionxt believes this technology represents a meaningful evolution of its oral thin-film platform, strengthening platform differentiation, intellectual property positioning and long-term life-cycle management strategies.

Potential therapeutic applications

The secured chaperone-enabled delivery technology is intended as a broad, scalable platform with potential application across oncology (including solid tumours such as breast, pancreatic and prostate cancers), neurological and neurodegenerative diseases (including Alzheimer's disease, Parkinson's disease, dementia and major depressive disorder), selected bacterial and fungal infections, and autoimmune diseases.

IP ownership, optionality and platform economics

Pursuant to the LOI, Bionxt would secure exclusive rights to the chaperone technology for oral-dissolvable applications, with all related intellectual property owned by Bionxt within the defined field of use. The proposed transaction contemplates a development road map, including prototype development and future patent filings in key jurisdictions, including Europe and the United States, reinforcing Bionxt's long-term intellectual property strategy in targeted drug delivery.

In addition, the LOI provides Bionxt with a right of first refusal to evaluate the acquisition of rights for non-oral delivery formats, highlighting longer-term platform optionality beyond ODFs. Bionxt intends to finance all development activities internally and continue executing a platform-driven commercialization strategy, including licensing and co-development opportunities.

The proposed transaction remains subject to the negotiation and execution of definitive agreements. There can be no assurance that such agreements will be completed on the terms currently contemplated, or at all.

About Bionxt Solutions Inc.

Bionxt Solutions is a bioscience innovator focused on next-generation drug delivery platforms, diagnostic screening systems and active pharmaceutical ingredient development. Its proprietary platforms include sublingual thin films, transdermal patches, oral tablets and a new targeted chemotherapy platform designed to deliver cancer drugs directly to tumours while reducing side effects.

With research and development operations in North America and Europe, Bionxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. Bionxt is committed to improving health care by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.

Bionxt is listed on the Canadian Securities Exchange under the symbol BNXT and on the OTC Markets under the symbol BNXTF and trades in Germany under WKN: A3D1K3.

We seek Safe Harbor.